title: Photodynamic therapy for symptomatic subretinal fluid related to choroidal nevus.
abstract: OBJECTIVE
  The purpose of this article is to evaluate the role of photodynamic therapy (PDT) for symptomatic choroidal nevus with subretinal fluid (SRF) extending to the fovea.
  
  
  METHODS
  Retrospective review of the medical records of all patients who underwent PDT for a symptomatic choroidal nevus with SRF.
  
  
  RESULTS
  Seventeen patients were included in the study. The mean initial visual acuity was 20/80 (range, counting fingers to 20/20). The mean initial tumor thickness was 1.23 mm (range, 0.66-1.93 mm). All tumors presented at least 2 risk factors for growing (including orange pigment, symptoms, peripapillary location, SRF, and thickness >2 mm). The mean number of PDT sessions was 1.41 (range, 1-3). The mean final visual acuity improved to 20/60 (range, counting fingers to 20/20). Subretinal fluid was reduced in all eyes (100%) and had completely disappeared in 9 eyes (53%) after PDT. Of 9 cases with complete resolution of the SRF, 2 patients (22%) presented recurrence. The mean final tumor thickness increased to 1.24 mm (range, 0.66-2.01 mm) at a mean follow-up of 22.47 months (range, 6-60 months). Tumor thickness increased in 3 eyes (18%) and remained unchanged in 13 eyes (76%), and 1 lesion (6%) shrank down to a flat chorioretinal scar.
  
  
  CONCLUSIONS
  Photodynamic therapy is a good treatment option to reduce SRF in symptomatic choroidal nevus with serous macular detachment. Further growth into melanoma was observed in 18% of cases. Thus, PDT may not allow a good local tumor control. Longer follow-up is required to determine its value in these patients.
authors.affiliation: Ophthalmology Department, Institute of Ocular Microsurgery, Barcelona, Spain.
authors.forename: Jose
authors.initials: J
authors.lastname: García-Arumí
authors.forename: Luis
authors.initials: L
authors.lastname: Amselem
authors.forename: Kaan
authors.initials: K
authors.lastname: Gunduz
authors.forename: Jose
authors.initials: J
authors.lastname: Badal
authors.forename: Alfredo
authors.initials: A
authors.lastname: Adan
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Zapata
authors.forename: Xavier
authors.initials: X
authors.lastname: Valldeperas
authors.forename: Frederic
authors.initials: F
authors.lastname: Huste
authors.forename: Borja
authors.initials: B
authors.lastname: Corcóstegui
mesh_terms: D000328:Adult; D000368:Aged; D002830:Choroid Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009508:Nevus, Pigmented / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D012189:Retrospective Studies; D058471:Subretinal Fluid / Q000378:metabolism*; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin